Fibronectin is a serum biomarker for Duchenne muscular dystrophy

Proteomics - Clinical Applications

Volumn 8, Issue 3-4, 2014, Pages 269-278

  Cynthia Martin, F ^a   Hiller, Monika ^a   Spitali, Pietro ^a   Oonk, Stijn ^a   Dalebout, Hans ^a   Palmblad, Magnus ^a   Chaouch, Amina ^b   Guglieri, Michela ^b   Straub, Volker ^b   Lochmüller, Hanns ^b   Niks, Erik H ^a   Verschuuren, Jan J G M ^a   Aartsma Rus, Annemieke ^a,b   Deelder, André M ^a   van der Burgt, Yuri E M ^a   't Hoen, Peter A C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Biomarker; Duchenne muscular dystrophy; Fibronectin; Spectral counting

Indexed keywords

BIOLOGICAL MARKER; FIBRONECTIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BECKER MUSCULAR DYSTROPHY; BETHLEM MYOPATHY; CHILD; CONTROLLED STUDY; DISEASE COURSE; DUCHENNE MUSCULAR DYSTROPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MYASTHENIA GRAVIS; MYOPATHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; CONTRACTURE; FEMALE; GENETICS; METABOLISM; MIDDLE AGED; MUSCULAR DYSTROPHIES; PATHOLOGY; PRESCHOOL CHILD; SKELETAL MUSCLE;

ADOLESCENT; ADULT; BIOMARKERS; CHILD; CHILD, PRESCHOOL; CONTRACTURE; FEMALE; FIBRONECTINS; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES; MUSCULAR DYSTROPHY, DUCHENNE; MYASTHENIA GRAVIS;

EID: 84898547717     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201300072     Document Type: Article

References (55)

1. Hawkridge, A. M., Muddiman, D. C., Annu. Rev. Anal. Chem. 2009, 2, 265-277.
2. Surinova, S., Schiess, R., Huettenhain, R., Cerciello, F. et al., On the development of plasma protein biomarkers. J. Proteome. Res. 2011, 10, 5-16.
3. Paulovich, A. G., Whiteaker, J. R., Hoofnagle, A. N., Wang, P., The interface between biomarker discovery and clinical validation: the tar pit of the protein biomarker pipeline. Proteomics Clin. Appl. 2008, 2, 1386-1402.
4. Anderson, N. L., Anderson, N. G., The human plasma proteome-history, character, and diagnostic prospects. Mol. Cell. Proteomics 2002, 1, 845-867.
5. Zhang, H., Liu, A. Y., Loriaux, P., Wollscheid, B. et al., Mass spectrometric detection of tissue proteins in plasma. Mol. Cell. Proteomics 2007, 6, 64-71.
6. Deconinck, N., Dan, B., Pathophysiology of Duchenne muscular dystrophy: current hypotheses. Pediatr. Neurol. 2007, 36, 1-7.
7. Emery, A. E. H., The muscular dystrophies. Lancet 2002, 359, 687-695.
8. Goemans, N., van den Hauwe, M., Wilson, R., van Impe, A. et al., Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids. Neuromuscul. Disord. 2013, 23, 618-623.
9. Mazzone, E. S., Pane, M., Sormani, M. P., Scalise, R. et al., 24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy. PLoS ONE 2013, 8, e52512.
10. McDonald, C. M., Henricson, E. K., Abresch, R. T., Florence, J. M., et al., The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: Longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve 2013, 48, 343-356.
11. Zatz, M., Rapaport, D., Vainzof, M., Passos-Bueno, M. R. et al., Serum creatine-kinase (CK) and pyruvate-kinase (PK) activities in Duchenne (DMD) as compared with Becker (BMD) muscular dystrophy. J. Neurol. Sci. 1991, 102, 190-196.
12. Manzur A. Y., Kuntzer T., Pike, M., Swan A. V., Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database System. Rev. 2008, CD003725.
13. Nadarajah, V. D., van Putten, M., Chaouch, A., Garrood, P. et al., Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD). Neuromuscul. Disord. 2011, 21, 569-578.
14. Alagaratnam, S., Mertens, B. J. A., Dalebout, J. C., Deelder, A. M. et al., Serum protein profiling in mice: Identification of Factor XIIIa as a potential biomarker for muscular dystrophy. Proteomics 2008, 8, 1552-1563.
15. Colussi, C., Banfi, C., Brioschi, M., Tremoli, E. et al., Proteomic profile of differentially expressed plasma proteins from dystrophic mice and following suberoylanilide hydroxamic acid treatment. Proteomics Clin. Appl. 2010, 4, 71-83.
16. Aebersold, R., Mann, M., Mass spectrometry-based proteomics. Nature 2003, 422, 198-207.
17. Hunt, D. F., Yates, J. R., Shabanowitz, J., Winston, S., Hauer, C. R., Protein sequencing by tandem mass-spectrometry. Proc. Natl. Acad. Sci. USA 1986, 83, 6233-6237.
18. Switzar, L., Giera, M., Niessen, W. M. A., Protein digestion: an overview of the available techniques and recent developments. J. Proteome Research 2013, 12, 1067-1077.
19. Kim, M.-S., Pandey, A., Electron transfer dissociation mass spectrometry in proteomics. Proteomics 2012, 12, 530-542.
20. Syka, J. E. P., Coon, J. J., Schroeder, M. J., Shabanowitz, J., Hunt, D. F., Peptide and protein sequence analysis by electron transfer dissociation mass spectrometry. Proc. Natl. Acad. Sci. USA 2004, 101, 9528-9533.
21. Zubarev, R. A., Kelleher, N. L., McLafferty, F. W., Electron capture dissociation of multiply charged protein cations. A nonergodic process. J. Am. Chem. Soc. 1998, 120, 3265-3266.
22. Molina, H., Matthiesen, R., Kandasamy, K., Pandey, A., Comprehensive comparison of collision induced dissociation and electron transfer dissociation. Anal. Chem. 2008, 80, 4825-4835.
23. Rifai, N., Gillette, M. A., Carr, S. A., Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 2006, 24, 971-983.
24. Bantscheff, M., Schirle, M., Sweetman, G., Rick, J., Kuster, B., Quantitative mass spectrometry in proteomics: a critical review. Anal. Bioanal. Chem. 2007, 389, 1017-1031.
25. Craig, R., Cortens, J. C., Fenyo, D., Beavis, R. C., Using annotated peptide mass spectrum libraries for protein identification. J. Proteome. Res. 2006, 5, 1843-1849.
26. Lundgren, D. H., Hwang, S. I., Wu, L., Han, D. K., Role of spectral counting in quantitative proteomics. Expert Rev. Proteomics 2010, 7, 39-53.
27. Zhu, W., Smith, J. W., Huang, C. M., Mass spectrometry-based label-free quantitative proteomics. J. Biomed. Biotechnol. 2010, 2010, 840518.
28. Deutsch, E. W., Mendoza, L., Shteynberg, D., Farrah, T. et al., A guided tour of the Trans-Proteomic Pipeline. Proteomics 2010, 10, 1150-1159.
29. de Bruin, J. S., Deelder, A. M., Palmblad, M., Scientific workflow management in proteomics. Mol. Cell. Proteomics 2012, 11, M111.010595.
30. Deutsch, E. W., Shteynberg, D., Lam, H., Sun, Z. et al., Trans-Proteomic Pipeline supports and improves analysis of electron transfer dissociation data sets. Proteomics 2010, 10, 1190-1195.
31. Shteynberg, D., Deutsch, E. W., Lam, H., Eng, J. K., et al., iProphet: multi-level integrative analysis of shotgun proteomic data improves peptide and protein identification rates and error estimates. Mol. Cell. Proteomics 2011, 10, M111.007690.
32. Desiere, F., Deutsch, E. W., King, N. L., Nesvizhskii, A. I. et al., The PeptideAtlas project. Nucleic Acids Res. 2006, 34, D655-D658.
33. Lam, H., Building and searching tandem mass spectral libraries for peptide identification. Mol. Cell. Proteomics 2011, 10, R111.008565.
34. Righetti, P. G., Boschetti, E., The proteominer and the fortyniners:Searching for gold nuggets in the proteomic arena. Cancer Genomics Proteomics 2009, 6, 65-66.
35. Huhn, C., Ruhaak, L. R., Wuhrer, M., Deelder, A. M., Hexapeptide library as a universal tool for sample preparation in protein glycosylation analysis. J. Proteomics 2012, 75, 1515-1528.
36. Frese, C. K., Altelaar, A. F. M., Hennrich, M. L., Nolting, D. et al., Improved peptide identification by targeted fragmentation using CID, HCD and ETD on an LTQ-Orbitrap velos. J. Proteome Res. 2011, 10, 2377-2388.
37. McCafferty, M. H., Lepow, M., Cho, E., Meuwissen, H. et al., Normal Fibronectin levels as a function of age in the pediatric population. Pediatr. Res. 1983, 17, 482-485.
38. Valletta, E. A., Bonazzi, L., Zuanazzi, R., Del Col, G. et al., Plasma fibronectin concentrations in healthy newborns and in children. Eur. J. Pediatr. 1988, 147, 68-70.
39. Zhou, L., Lu, H., Targeting fibrosis in Duchenne muscular dystrophy. J. Neuropathol Exp. Neurol. 2010, 69, 771-776.
40. Babu, M., Diegelmann, R., Oliver, N., Fibronectin is overproduced by keloid fibroblasts during abnormal wound-healing. Mol. Cell. Biol. 1989, 9, 1642-1650.
41. Mann, C. J., Perdiguero, E., Kharraz, Y., Aguilar, S. et al., Aberrant repair and fibrosis development in skeletal muscle. Skelet. Muscle 2011, 1, 21.
42. Pescatori, M., Broccolini, A., Minetti, C., Bertini, E. et al., Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression. FASEB J. 2007, 21, 1210-1226.
43. Desguerre, I., Mayer, M., Leturcq, F., Barbet, J. P. et al., Endomysial fibrosis in Duchenne muscular dystrophy: a marker of poor outcome associated with macrophage alternative activation. J. Neuropathol Exp. Neurol. 2009, 68, 762-773.
44. Wynn, T. A., Barron, L., Macrophages: master regulators of inflammation and fibrosis. Semin. Liver Dis. 2010, 30, 245-257.
45. Nadarajah, V. D., van Putten, M., Chaouch, A., Garrood, P. et al., Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD). Neuromuscul. Disord. 2011, 21, 569-578.
46. Opdenakker, G., Van den Steen, P. E., Van, D. J., Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol. 2001, 22, 571-579.
47. Thant, A. A., Nawa, A., Kikkawa, F., Ichigotani, Y. et al., Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells. Clin. Exp. Metastasis 2001, 18, 423-428.
48. Xie, B., Laouar, A., Huberman, E., Fibronectin-mediated cell adhesion is required for induction of 92-kDa type IV collagenase/gelatinase (MMP-9) gene expression during macrophage differentiation-the signaling role of protein kinase C-beta. J. Biol. Chem. 1998, 273, 11576-11582.
49. Schwartz, E., Mezick, J. A., Gendimenico, G. J., Kligman, L. H., In vivo prevention of corticosteroid-induced skin atrophy by tretinoin in the hairless mouse is accompanied by modulation of collagen, glycosaminoglycans, and fibronectin. J. Invest Dermatol. 1994, 102, 241-246.
50. Miller, M., Cho, J. Y., McElwain, K., McElwain, S. et al., Corticosteroids prevent myofibroblast accumulation and airway remodeling in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 2006, 290, L162-L169.
51. Tomic, R., Lassiter, C. C., Ritzenthaler, J. D., Rivera, H. N., Roman, J., Anti-tissue remodeling effects of corticosteroids-fluticasone propionate inhibits fibronectin expression in fibroblasts. Chest 2005, 127, 257-265.
52. Andreetta, F., Bernasconi, P., Baggi, F., Ferro, P. et al., Immunomodulation of TGF-beta1 in mdx mouse inhibits connective tissue proliferation in diaphragm but increases inflammatory response: Implications for antifibrotic therapy. J. Neuroimmunol. 2006, 175, 77-86.
53. Cohn, R. D., van Erp, C., Habashi, J. P., Soleimani, A. A. et al., Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states (vol 12, pg 204, 2007). Nat. Med. 2007, 13, 511-511.
54. Li, Z. B., Zhang, J., Wagner, K. R., Inhibiting myostatin reverses muscle fibrosis through apoptosis. J. Cell Sci. 2012, 125, 3957-3965.
55. Verhaart, I. E. C., Aartsma-Rus, A., Gene therapy for Duchenne muscular dystrophy. Current Opin. Neurol. 2012, 25, 588-596.